APGE

Apogee Therapeutics, Inc.

Insider Trades

NameValueActionPriceCurrent Price
Dambkowski CarlChief Medical Officer
$433k5.5k shares
SellJun 3, 2026
$78.71
--
Henderson Michael ThomasDirector, Officer: Chief Executive Officer
$1.5M18.7k shares
SellMay 13, 2026
$82.05
--
Henderson Michael ThomasDirector, Officer: Chief Executive Officer
$111k1.3k shares
SellMay 13, 2026
$82.58
--
Dambkowski CarlChief Medical Officer
$311k3.7k shares
SellMay 6, 2026
$83.92
--
Dambkowski CarlChief Medical Officer
$152k1.8k shares
SellMay 6, 2026
$84.60
--
Henderson JaneChief Financial Officer
$74k900 shares
SellMay 1, 2026
$82.60
--

News

reuters.comAbbVie nears $11 billion deal for Apogee Therapeutics, FT reportsreuters.comJun 19marketbeat.comApogee Therapeutics Maps Phase 3 Push for Zumilokibart, Backed by Blackstone Fundingmarketbeat.comJun 10seekingalpha.comApogee Therapeutics, Inc. (APGE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcriptseekingalpha.comJun 10marketbeat.comApogee Therapeutics Readies Zumi for Phase 3 With Blackstone Backingmarketbeat.comJun 4seekingalpha.comApogee Therapeutics, Inc. (APGE) Discusses Positive Part B Results From Phase 2 APEX Trial of Zumilokibart in Atopic Dermatitis Transcriptseekingalpha.comJun 1